Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Paul Barraclough
Paul Barraclough, Kent GB
| Patent application number | Description | Published |
|---|---|---|
| 20090023807 | Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a monoglyceride or metabolic precursor thereof of general formula (I), wherein R | 01-22-2009 |
| 20090036410 | Structured Phospholipids - A method of treating a patient in need of therapy for a disease in which cyokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterifed with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of γ-linolenoyl, dihomo-γ-linolenoyl acid and arachidonoyl. | 02-05-2009 |
| 20090137660 | Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 05-28-2009 |
| 20090291954 | Medical Use of Triazine Derivatives - Compounds of formula (I) especially where R | 11-26-2009 |
| 20100297196 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 11-25-2010 |
Paul Barraclough, Surrey GB
| Patent application number | Description | Published |
|---|---|---|
| 20100113595 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 05-06-2010 |
| 20100113810 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 05-06-2010 |
Paul Barraclough, Maidstone GB
| Patent application number | Description | Published |
|---|---|---|
| 20080207576 | Substituted sapogenins and their use - The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed | 08-28-2008 |
| 20100087411 | SUBSTITUTED SAPOGENINS AND THEIR USE - The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed | 04-08-2010 |